Details

Autor(en) / Beteiligte

• Kumar, Shaji
• Giralt, Sergio
• Stadtmauer, Edward A.
• Harousseau, Jean L.
• Palumbo, Antonio
• Bensinger, William
• Comenzo, Raymond L.
• Lentzsch, Suzanne
• Munshi, Nikhil
• Niesvizky, Ruben
• San Miguel, Jesus
• Ludwig, Heinz
• Bergsagel, Leif
• Blade, Joan
• Lonial, Sagar
• Anderson, Kenneth C.
• Tosi, Patrizia
• Sonneveld, Pieter
• Sezer, Orhan
• Vesole, David
• Cavo, Michele
• Einsele, Hermann
• Richardson, Paul G.
• Durie, Brian G.M.
• Rajkumar, S. Vincent

Titel

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Ist Teil von

• Blood, 2009-08, Vol.114 (9), p.1729-1735

Ort / Verlag

Washington, DC: Elsevier Inc

Erscheinungsjahr

2009

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization.